Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.
PURPOSE: Randomized phase II trial to study the effectiveness of vaccine therapy in treating
patients who have high-risk stage III or completely resected metastatic melanoma.